Skip to main content

Compare Stocks

Date Range: 

 Akebia TherapeuticsViking TherapeuticsInozyme PharmaKala PharmaceuticalsAltimmune
SymbolNASDAQ:AKBANASDAQ:VKTXNASDAQ:INZYNASDAQ:KALANASDAQ:ALT
Price Information
Current Price$3.50$6.03$15.95$5.41$14.07
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.61.71.71.8
Analysis Score3.33.63.53.43.5
Community Score2.73.52.82.63.4
Dividend Score0.00.00.00.00.0
Ownership Score1.70.81.71.71.7
Earnings & Valuation Score0.60.00.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$7.83$16.89$36.00$21.33$31.75
% Upside from Price Target123.81% upside180.08% upside125.71% upside294.33% upside125.66% upside
Trade Information
Market Cap$560.40 million$470.94 million$374.55 million$349.71 million$522.70 million
Beta2.112.02N/A0.431.51
Average Volume5,504,3351,245,04255,9462,370,4351,405,161
Sales & Book Value
Annual Revenue$335 millionN/AN/A$6.07 million$5.80 million
Price / Sales1.67N/AN/A57.6190.12
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.32 per share$3.83 per shareN/A$0.86 per share$2.97 per share
Price / Book1.05N/AN/A6.294.74
Profitability
Net Income$-279,660,000.00$-25,780,000.00N/A$-94,350,000.00$-20,520,000.00
EPS($1.63)($0.36)N/A($2.76)($0.98)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/A24.68
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-126.86%N/AN/A-1,794.36%-659.33%
Return on Equity (ROE)-68.51%-13.57%N/A-93.73%-46.39%
Return on Assets (ROA)-34.01%-13.14%N/A-43.09%-38.32%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.24%N/AN/A0.68%N/A
Current Ratio2.15%27.08%16.71%9.11%34.66%
Quick Ratio1.67%27.09%16.71%8.73%34.66%
Ownership Information
Institutional Ownership Percentage68.98%54.13%69.77%67.63%66.22%
Insider Ownership Percentage2.55%3.70%N/A34.15%2.70%
Miscellaneous
Employees379183818843
Shares Outstanding160.12 million78.10 million23.48 million64.64 million37.15 million
Next Earnings Date8/9/2021 (Estimated)8/4/2021 (Estimated)9/2/2021 (Estimated)8/5/2021 (Estimated)8/10/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Altimmune (NASDAQ:ALT) Posts  Earnings Results, Beats Expectations By $0.01 EPSAltimmune (NASDAQ:ALT) Posts Earnings Results, Beats Expectations By $0.01 EPS
americanbankingnews.com - May 18 at 7:24 AM
Altimmune Inc (ALT) has risen 7.42% in a Week, Should You Sell? - InvestorsObserverAltimmune Inc (ALT) has risen 7.42% in a Week, Should You Sell? - InvestorsObserver
investorsobserver.com - May 17 at 10:42 PM
Altimmune awaits Covid vaccine results, preps next trials for AdCovid intranasal spray - Washington Business Journal - Washington Business JournalAltimmune awaits Covid vaccine results, preps next trials for AdCovid intranasal spray - Washington Business Journal - Washington Business Journal
bizjournals.com - May 17 at 5:42 PM
Looking Into Altimmunes Return On Capital Employed - BenzingaLooking Into Altimmune's Return On Capital Employed - Benzinga
benzinga.com - May 17 at 2:20 PM
Altimmune Q1 loss soars 282% as expenses rise dramatically; shares up ~3% - Seeking AlphaAltimmune Q1 loss soars 282% as expenses rise dramatically; shares up ~3% - Seeking Alpha
seekingalpha.com - May 17 at 1:45 PM
Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update - BioSpaceAltimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update - BioSpace
biospace.com - May 17 at 1:45 PM
ALTIMMUNE INC (ALT) Q1 2021 Earnings Call Transcript - Motley FoolALTIMMUNE INC (ALT) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - May 17 at 12:42 PM
Altimmune Posts Q1 Loss Per Share $0.38 - CMLViz.com - CML NewsAltimmune Posts Q1 Loss Per Share $0.38 - CMLViz.com - CML News
cmlviz.com - May 17 at 12:42 PM
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo FinanceAltimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 17 at 12:42 PM
Form 10-Q Altimmune, Inc. For: Mar 31 - StreetInsider.comForm 10-Q Altimmune, Inc. For: Mar 31 - StreetInsider.com
streetinsider.com - May 17 at 7:41 AM
ALTIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.comALTIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - marketscreener.com
marketscreener.com - May 17 at 7:41 AM
Altimmune Announces First Quarter 2021 Financial Results - GlobeNewswireAltimmune Announces First Quarter 2021 Financial Results - GlobeNewswire
globenewswire.com - May 17 at 7:41 AM
Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate UpdateAltimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 17 at 7:41 AM
Altimmune earnings: heres what Wall Street expectsAltimmune earnings: here's what Wall Street expects
markets.businessinsider.com - May 16 at 8:31 AM
Altimmune Inc Registered Shs hosts conference call for investorsAltimmune Inc Registered Shs hosts conference call for investors
markets.businessinsider.com - May 15 at 12:41 AM
UAB: Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity In Preclinical Tests - Patch.comUAB: Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity In Preclinical Tests - Patch.com
patch.com - May 13 at 10:40 PM
Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Buy" from BrokeragesAltimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Buy" from Brokerages
americanbankingnews.com - May 13 at 1:38 AM
The Altimmune (NASDAQ:ALT) Share Price Has Gained 261%, So Why Not Pay It Some Attention? - NasdaqThe Altimmune (NASDAQ:ALT) Share Price Has Gained 261%, So Why Not Pay It Some Attention? - Nasdaq
nasdaq.com - May 12 at 1:01 PM
Altimmune (ALT) to Release Earnings on MondayAltimmune (ALT) to Release Earnings on Monday
americanbankingnews.com - May 12 at 9:52 AM
Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating - Investors Business DailyAltimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
investors.com - May 11 at 3:39 PM
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021 - Yahoo FinanceAltimmune to Announce First Quarter 2021 Financial Results on May 17, 2021 - Yahoo Finance
finance.yahoo.com - May 11 at 1:05 PM
Altimmune - Consensus Indicates Potential 223.5% Upside - DirectorsTalk InterviewsAltimmune - Consensus Indicates Potential 223.5% Upside - DirectorsTalk Interviews
directorstalkinterviews.com - May 11 at 9:16 AM
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
finance.yahoo.com - May 11 at 8:04 AM
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
investorplace.com - May 10 at 9:36 AM
Thinking about buying stock in Polarityte, AMC Entertainment, Altimmune, iHeartMedia, or Vale? - PRNewswireThinking about buying stock in Polarityte, AMC Entertainment, Altimmune, iHeartMedia, or Vale? - PRNewswire
prnewswire.com - May 10 at 9:36 AM
DateCompanyBrokerageAction
3/15/2021Akebia TherapeuticsHC WainwrightLower Price Target
3/15/2021Akebia TherapeuticsCantor FitzgeraldInitiated Coverage
1/29/2021Akebia TherapeuticsJPMorgan Chase & Co.Downgrade
9/4/2020Akebia TherapeuticsMorgan StanleyLower Price Target
9/4/2020Akebia TherapeuticsBTIG ResearchLower Price Target
9/4/2020Akebia TherapeuticsMizuhoLower Price Target
8/11/2020Akebia TherapeuticsNeedham & Company LLCInitiated Coverage
5/6/2020Akebia TherapeuticsRoyal Bank of CanadaBoost Price Target
5/3/2021Viking TherapeuticsSVB LeerinkReiterated Rating
1/22/2021Viking TherapeuticsStifel NicolausReiterated Rating
10/29/2020Viking TherapeuticsRaymond JamesBoost Price Target
9/11/2020Viking TherapeuticsWilliam BlairReiterated Rating
9/10/2020Viking TherapeuticsB. RileyReiterated Rating
8/31/2020Viking TherapeuticsChardan CapitalBoost Price Target
7/29/2020Viking TherapeuticsOppenheimerReiterated Rating
6/4/2020Viking TherapeuticsBMO Capital MarketsInitiated Coverage
5/2/2020Viking TherapeuticsMaxim GroupInitiated Coverage
8/18/2020Inozyme PharmaWedbushInitiated Coverage
8/18/2020Inozyme PharmaBank of AmericaInitiated Coverage
8/18/2020Inozyme PharmaPiper SandlerInitiated Coverage
8/18/2020Inozyme PharmaCowenInitiated Coverage
11/30/2020Kala PharmaceuticalsNorthland SecuritiesReiterated Rating
9/14/2020Kala PharmaceuticalsJefferies Financial GroupDowngrade
2/10/2021AltimmuneGuggenheimInitiated Coverage
11/24/2020AltimmuneEvercore ISIReiterated Rating
7/28/2020AltimmuneJMP SecuritiesInitiated Coverage
2/24/2020AltimmuneRoth CapitalInitiated Coverage
5/29/2018AltimmuneDawson JamesReiterated Rating
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.